drugset
drugset / Trial / NCT05758818

A Study of Milademetan Administration on Cardiac Repolarization in Healthy Subjects

NCT05758818 ↗

Phase 1 Terminated 6 enrolled Rain Oncology Inc
RandomizedSequentialTriple-blindTreatment

Summary

This will be a Phase 1, single-center, 2-part study in healthy subjects. Parts 1 and 2 need to be conducted in sequential order.

Timeline

Start
2023-04-17
Primary completion
2023-06-08
Completion
2023-06-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Milademetan Small molecule 260 mg Oral
Subject Milademetan Small molecule 300 mg Oral
Subject Milademetan Small molecule 330 mg Oral
Subject Milademetan Small molecule 360 mg Oral
Comparator Moxifloxacin Small molecule 400 mg Oral

Indications

No indication recorded.